Journal Top Ten -- COLUMNS-Drug & Supplements--September 2007

1
Avandia

ARTICLE: 'Long-term Risk of Cardiovascular Events with Rosiglitazone: A Meta-Analysis'

JOURNAL: JAMA 2007 Sep 12;298(10):1189-95

SUMMARY: This systematic review of long-term cardiovascular risks associated with Avandia included an analysis of data from sources including Medline, the GlaxoSmithKline clinical trials register and the FDA. Studies were selected based on the requirement that they were randomized controlled trials for prevention or treatment of Type 2 diabetes, had a minimum follow-up of 12 months and provided for monitoring of cardiovascular events and included numerical data for all adverse events. The results indicated that Avandia significantly increased the …